The last 15 years or so have seen exciting progress in xenotransplantation, with porcine organ grafts surviving months or even years in non-human primates. These advances reflect the application of new scientific knowledge, improved immunosuppressive agents, and genetic engineering. The field has recently enjoyed a renaissance of interest and hope, largely due to the exponential increase in our capacity to genetically engineer porcine source animals. However, immune responses to xenografts are very powerful and widespread clinical application of xenotransplantation will depend on the ability to suppress these immune responses while preserving the capacity to protect both the recipient and the graft from infectious microorganisms. Our work over the last three decades has aimed to engineer the immune system of the recipient in a manner that achieves specific tolerance to the xenogeneic donor while preserving otherwise normal immune function. Important proofs of principle have been obtained, first in rodents, and later in human immune systems in "humanized mice" and finally in non-human primates, demonstrating the capacity and potential synergy of mixed xenogeneic chimerism and xenogeneic thymic transplantation in tolerizing multiple arms of the immune system. Considering the fact that clinical tolerance has recently been achieved for allografts and the even greater importance of avoiding excessive immunosuppression for xenografts, it is my belief that it is both possible and imperative that we likewise achieve xenograft tolerance. I expect this to be accomplished through the availability of targeted approaches to recipient immune conditioning, understanding of immunological mechanisms of tolerance, advanced knowledge of physiological incompatibilities, and the availability of inbred miniature swine with optimized use of genetic engineering.
a renaissance of interest and hope, largely due to the exponential increase in our capacity to genetically engineer porcine source animals. However, immune responses to xenografts are very powerful and widespread clinical application of xenotransplantation will depend on the ability to suppress these immune responses while preserving the capacity to protect both the recipient and the graft from infectious microorganisms. Our work over the last three decades has aimed to engineer the immune system of the recipient in a manner that achieves specific tolerance to the xenogeneic donor while preserving otherwise normal immune function. Important proofs of principle have been obtained, first in rodents, and later in human immune systems in "humanized mice" and finally in non-human primates, demonstrating the capacity and potential synergy of mixed xenogeneic chimerism and xenogeneic thymic transplantation in tolerizing multiple arms of the immune system. Considering the fact that clinical tolerance has recently been achieved for allografts and the even greater importance of avoiding excessive immunosuppression for xenografts, it is my belief that it is both possible and imperative that we likewise achieve xenograft tolerance. I expect this to be accomplished through the availability of targeted approaches to recipient immune conditioning, understanding of immunological mechanisms of tolerance, advanced knowledge of physiological incompatibilities, and the availability of inbred miniature swine with optimized use of genetic engineering.
K E Y W O R D S
B cell, CD47, human, humanized mouse, macrophage, miniature swine, mixed chimerism, mouse, natural antibody, natural killer cell, pig, rat, T cell, thymus, tolerance, xenotransplantation
| INTRODUC TI ON
We have witnessed encouraging progress toward clinical application of organ and cellular of xenotransplantation over the last 40 years.
Recognition of the role of natural antibodies in causing hyperacute rejection (HAR) led to studies of plasma absorption by perfusion through xenogeneic organs in the 1980s that prolonged the survival of implanted organs from minutes to hours.
1,2 The development of the first transgenic pigs expressing human complement regulatory proteins led to further advancement, permitting organ survivals of days to weeks in the 1990s. [3] [4] [5] The seminal discovery of α1,3Gal
as the major antigenic target of human natural antibodies binding to porcine endothelial cells, [6] [7] [8] [9] combined with the development of mammalian nuclear transfer and cloning technologies, permitted the generation of pigs lacking a functional α1,3Gal transferase (αGalT) gene and hence lacking the target of these natural antibodies, in the early 2000s. [10] [11] [12] This breakthrough, combined with advances in immunosuppression, permitted further prolongation of porcine organ xenograft survival in non-human primates for weeks to several months. [13] [14] [15] [16] [17] [18] [19] The αGalT KO was usually combined with one or more transgenes encoding a human complement regulatory protein in these studies. The newer immunosuppressive regimens, independent of the αGalT KO advance, also permitted porcine islet xenografts to survive for more than 6 months in non-human primates (NHPs) in this period. [20] [21] [22] These immunosuppressive regimens typically included costimulatory blockade and rapamycin. However, the T-cell immune response to islet xenografts has not been fully suppressed by these multidrug regimens, resulting in their eventual rejection. While encapsulation of xenogeneic islets has shown promise, permanent graft survival has not been achieved with this strategy alone. 23, 24 Thus, tolerance is likely to be needed to overcome the powerful T cell-mediated immune responses to xenografts while preserving adequate recipient immune function.
The 2010s have seen further exciting advances, such as heterotopic cardiac xenograft survival for greater than a year in baboons when αGalT KO, human CD46 and thrombomodulin transgenic pig hearts were transplanted with a costimulation blockade-based immunosuppressive regimen. 25 However, antibody-mediated rejection developed quickly when the dosage of anti-CD40 antibody was reduced. Considerable optimism has been attached to the field of xenotransplantation in recent years, partly because of these advances and in large part due to advances in genetic engineering and gene editing technologies that are rapidly being applied to pigs used in NHP xenotransplantation studies, as we heard at this meeting.
Indeed, one of the challenges now facing us is the need to dissect the role of each new genetic modification in improving xenograft survival, as each one will need to be justified if it is to be used in a clinically approved source animal.
Some genetic engineering approaches are aimed at making xenogeneic organs invisible to the immune system or resistant to immune attack. There are a few limitations to this approach that need to be considered. One is that the absence of porcine MHC antigens would likely render such xenografts susceptible to infection, as T lymphocytes would have no way of recognizing cells that lack MHC molecules required to present foreign peptides. Indeed, when considering xenotransplantation, we must think about the impact of infection or viral reactivation on the xenograft itself and how the immune system will respond to it. It has been clearly demonstrated that porcine cytomegalovirus (CMV) reactivation on xenografts results in widespread immune activation and early graft loss 26 and the lack of adaptive immunity to the porcine CMV is likely to be a contributing factor to these dramatic effects of its reactivation.
Expression of inhibitory surface markers by the xenograft or secretion of soluble immunosuppressive proteins might have similar consequences. Furthermore, the absence of class I MHC could make xenografts more susceptible to natural killer (NK) cell-mediated rejection, a problem that could potentially be overcome by transgenic
HLA-E molecules. 27, 28 A third limitation is that invisibility to direct immune attack would not obviate indirect recognition of xenoantigens and associated effector mechanisms, including those mediated by de novo antibody formation against the donor.
Tolerance induction has an important role to play in combina- 
| LE SSON S FROM MIXED CHIMERIS M INDUC TI ON IN RODENT AND H UMANIZED MOUS E XENOG R AF T MODEL S
A major requirement for the use of hematopoietic cell transplantation (HCT) for the purpose of inducing organ graft tolerance (in contrast to its more common use to treat a life-threatening malignancy) is that the preparative regimen for engraftment of donor hematopoietic cells must be non-myeloablative. In other words, recipient hematopoietic cells must not be fully ablated by the conditioning regimen, so a failure or loss of donor engraftment will not be associated with hematopoietic failure. A second requirement is that the regimen must have relatively low toxicity and be free of the risk of graft-vs-host disease (GVHD The mechanisms of T-cell tolerance induction in the rat→mouse model were found to be similar to those involved in the allogeneic non-myeloablative bone marrow transplant model upon which it was based, with a major role for central deletion of newly-developing donor-reactive thymocytes, 33 which correlated with the appearance of rat MHC class II+ antigen-presenting cells in the recipient thymus. 40 This tolerance was observed both in vitro and in vivo, with marked and specific prolongation of donor rat skin grafts.
29
We subsequently developed a robust humanized mouse model that exhibited spontaneous porcine islet and skin graft rejection by implanting human fetal thymus tissue and infusing human CD34+ cells intravenously to immunodeficient mice. 41, 42 Using immunodeficient mice that were genetically engineered to express porcine hema- In addition to T-cell tolerance, our early studies demonstrated disappearance of pre-existing natural IgM antibodies against the rat donor following induction of mixed xenogeneic chimerism in mice. 35, [44] [45] [46] As passive transfer studies showed that these mouse Nabs could inhibit rat marrow engraftment, 47 these observations were consistent with the possibility that mouse Nabs bound to the rat hematopoietic cells were adsorbed from the circulation and that the Nabs were responsible for the gradual loss of chimerism. However, the absence of measurable anti-rat Nabs persisted as the chimerism declined 34 and studies in immunodeficient mice demonstrated a similar decline in rat chimerism in the absence of natural antibodies. 37 These data suggested that tolerance of Nab-forming B cells may have developed and persisted despite the decline of rat chimerism, which likely reflected "out-competition" by the recipient (mouse) hematopoietic cells. Indeed, when αGalT-deficient mice, which resemble humans in producing Nab against αGal, 48 became available, we used Elispot assays to demonstrate that mixed chimerism in both the wild-type to knockout mouse 49, 50 and xenogeneic rat to αGal knockout mouse model 51 was associated with true tolerance of Nabforming B cells to the donor. Although most of these anti-αGal Nabs were of the IgM class, pre-immunization of the αGalT knockout recipients with αGal+ rabbit erythrocytes induced IgG anti-αGal antibodies in these mice. While increased doses of bone marrow were required to overcome this additional anti-αGal antibody barrier to engraftment, 52 tolerance of anti-αGal antibody-forming cells was again achieved once the cells engrafted. In this rat→ αGalT knockout mouse model, induction of mixed chimerism protected primarily vascularized rat xenografts (hearts) from all forms of rejection, including hyperacute and acute vascular rejection, which occurred in conditioned control animals 51 in which natural xenoantibodies are increased due to loss of T-cell regulation. 53 They were also protected from cell-mediated and chronic rejection. 51 Together, these encouraging studies demonstrate the potential of mixed chimerism to tolerize donor-reactive T cells robustly, also preventing induced antibody responses and tolerizing T cell-independent Nab-producing B cells.
One advantage of this approach over genetic modification of pigs to eliminate targets of natural antibodies is that all specificities of Nab-forming B cells are tolerized by mixed chimerism, obviating the need to know what these specificities are and thus the need to progressively knock out more and more porcine genes as additional targets are identified. The latter approach poses both potential risks to the health of the porcine source animals as well as the risk that new specificities will be revealed as existing carbohydrate targets are removed from these pigs. Thus, mixed chimerism may be the optimal way to overcome the natural antibody barrier to xenografts.
With knowledge of the αGal ligand of these Nab-forming B cells, we were able to probe the recipient B cell repertoire for the presence of anti-αGal B cells at various stages in the tolerance process, permitting elucidation of the mechanisms of B cell tolerance in mixed chimeras. These studies revealed that initial, early tolerance was due to anergy of αGal-binding B cells, whereas the longer-term B cell tolerance was associated with deletion of these cells from the repertoire. 50, 51, 54 While the early anergy was reversible by transfer of anti-αGal-forming cells to a non-αGal-containing environment, the later deletional tolerance, as expected, could not be reversed by removal of B cells from the αGal-containing environment. We used the humanized mouse model described above, in which mixed xenogeneic (porcine and human) chimerism can be induced in pig cytokine transgenic immunodeficient mice, to assess the ability of pig chimerism to tolerize human NK cells. As NK cells require IL-15 to develop and mouse IL-15 does not bind to the human IL-15 receptor, it was necessary to administer human cytokines to these mixed xenogeneic chimeras to induce human NK cell development. In such animals, we observed that, while human NK cells developing in non-chimeric mice were able to kill and produce cytokines in response to porcine lymphoblasts, those developing in mixed xenogeneic chimeras lacked cytolytic activity against porcine lymphoblasts. In some such animals, the lack of pig-specific killing was associated with a failure to kill the human class I MHC-deficient target K562 (ie, global hyporesponsiveness), whereas in others the tolerance was donor-specific and associated with significant ability to lyse K562 targets. 77 These results are consistent with the observation that many human killer inhibitory receptors (KIRs) do not interact with porcine MHC molecules, whereas a few receptors do. 78 On balance, however, our 
| TR ANS L ATING MIXED CHIMERIS M TO THE L ARG E ANIMAL PI G -TO -PRIMATE MODEL
The studies in pig-human chimeras in immunodeficient mice and in Furthermore, antibody-independent complement activation also promotes clearance of xenogeneic cells. 90 The latter barrier may be overcome by the transgenic expression of human complement regulatory proteins in existing porcine source animals, whereas the former obstacle has required additional genetic modifications of pigs.
In particular, CD47 is an inhibitory ligand required for the inhibition of macrophage-mediated phagocytosis of hematopoietic cells. 91 The porcine CD47 molecule, however, does not transmit an inhibitory signal to human macrophages through the inhibitory receptor SIRPα, resulting in activation of human macrophages and engulfment of porcine hematopoietic cells. 92, 93 Thus, introduction of a human CD47 transgene is likely to be needed to prevent the rapid destruction of porcine hematopoietic cells by human macrophages. Indeed, the introduction of a human CD47 molecule into the Sachs miniature swine line greatly prolonged the survival of porcine hematopoietic cells both in mice expressing a SIRPα allele that transmits an inhibitory signal from human CD47 94 and in non-human primates.
95
Prolonged porcine chimerism in baboons receiving hCD47 transgenic porcine hematopoietic cell transplantation was associated with remarkable prolongation of porcine skin xenograft survival.
In studies presented at this congress, polyclonal recipient regulatory 
| THYMIC TR AN S PL ANTATI ON FOR THE INDUC TION OF XENOG R AF T TOLER AN CE
In view of the early obstacles encountered to the induction of mixed xenogeneic (porcine) chimerism in non-human primate models as discussed above, we developed an alternative approach to achieving Tregs. 102 Indeed, adoptive transfer studies revealed that the disease was due to both a failure to select Tregs that prevented autoimmunity and incomplete deletion of effector T cells that could cause disease. 108 To reconcile the observed deletion of T cells recognizing antigens presented by murine APCs with the multiorgan autoimmune disease, we hypothesize that autoimmunity reflects the inability of porcine thymic epithelial cells to produce mouse host-specific tissue-restricted antigens (TRAs), and hence to delete T cells with these specificities or to generate Tregs recognizing them, as occurs during normal thymic development.
109-113
The porcine thymic transplantation approach to tolerance has been extended to the humanized mouse model to provide proofof-principle that human T cells can develop normally and are centrally tolerized to porcine xenoantigens in pig thymic grafts.
114,115
Both thymic and peripheral human T cells developing in a porcine Thymi were transplanted either as part of a composite "thymokidney" graft prepared in the donor pig several months earlier by placing autologous thymic fragments under the pig's kidney capsule or by direct vascular anastomosis of a pig thymic lobe in a baboon.
16
Both approaches led, for the first time, to long-term survival of GalT knockout pig kidneys in baboons. 16, 119 Survival of animals receiving this treatment has been limited by thrombotic complications of anti-CD40L and by proteinuria due to a minimal change disease-like glomerulopathy, which can be avoided using non-thrombogenic anti-CD40 and by administering rituximab and CTLA4Ig, 120 respectively. Interestingly, work presented at this meeting suggests that transgenic expression of human CD47 on porcine glomeruli also appears to mitigate proteinuria due to this glomerulopathy. 121 We 
| CON CLUS IONS
While the road to xenograft tolerance may be aptly described as having been long and winding thus far, the important proofs of principle that have been obtained both in humanized mouse models and in pig-to-baboon models of thymic and hematopoietic cell transplantation for tolerance induction encourage the pursuit of this important goal, which is likely to be critical for the widespread clinical success of xenotransplantation. Indeed, the ability of mixed chimerism to tolerize both adaptive and innate components of the immune response suggests a way of minimizing the number of genetic modifications of porcine source animals that will be needed to assure success. For example, while lung xenografts appear to be especially sensitive to early rejection in the presence of low levels of natural antibodies, 98 the ability of mixed chimerism to tolerize Nab-producing B cells without knowing their specificity obviates the requirement to eliminate every possible carbohydrate target from porcine source animals. The human CD47 transgene appears to be particularly salutary, not only in having the predicted effect of prolonging porcine hematopoietic cell chimerism in primates, but also, somewhat unexpectedly, in improving the survival of porcine kidney and lung xenografts through mechanisms that remain to be dissected. Thus, porcine source animals lacking αGal and perhaps β4Gal 124, 125 and expressing human CD47 as well as complement and hematopoietic cytokine receptors may be sufficient to permit the goal of long-term tolerance to be achieved. Data obtained in conventional pig-to-miniature pig transplantation 122 and in pig-to-primate xenotransplantation 126 suggest that the ideal source animal will be a miniature swine, as intrinsic growth properties of the graft seem likely to limit the success of transplantation from conventional pigs.
Xenotransplantation lends itself to tolerance induction more readily than allotransplantation from deceased human donors, as the ability to perform xenotransplantation electively permits the application of a tolerance protocol (eg, mixed chimerism induction) in advance of the organ xenograft. It will thereby be possible to tolerize the immune system first, confirm that tolerance has been achieved and subsequently perform the organ transplant without immunosuppression. The availability of miniature swine that have been inbred for over 40 years 127 is a major asset for this purpose, as the HSC or thymic donor will tolerize the recipient to the same porcine antigens as those expressed by the subsequent organ source animal. Our studies have shown that, while there may some degree of hyporesponsiveness to the donor species overall (compared to allogeneic donors), complete and specific T-cell tolerance is only achieved to xenogeneic animals of the same "strain" as that used to induce the tolerance. 16, 29, 43, 114, 115, 122 Further advantages of using inbred animals in xenotransplantation include the consistency and standardization of source animals and the ability to combine genetic modifications at different loci without adding further genetic variability each time an animal is bred. Therefore, inbred miniature swine are uniquely suited to the promising approach of xenograft tolerance induction.
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